Income statement
USD
Annual
| Metric | 2025 |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -168K |
| EBITDA | -168K |
| Net Income | 382K |
| EPS (Diluted) | — |
Financial Services
Live Price
Offline$13.86
+11.41% today
Window Change
+35.09%
Window
Feb 9, 2026 → Jun 26, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 96 bars · Feb 9, 2026 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ChemoCentryx Inc (CCXI) is a Financial Services stock with a market cap of $430.00M and listed on NASDAQ. The stock last traded around $13.86 and up 35.1% across the available one-year price window (Feb 9, 2026 → Jun 26, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC -0.0%. Valuation already assumes a fairly strong business story at P/E 1492.7. Stock Foundry combines CCXI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CCXI
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CCXI Max Drawdown
-1.66%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CCXI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
$382.1K
Free Cash Flow
-$632.8K
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -168K |
| EBITDA | -168K |
| Net Income | 382K |
| EPS (Diluted) | — |
Balance sheet
USD
| Metric | 2025 |
|---|---|
| Cash & Equivalents | 736K |
| Total Assets | 416M |
| Total Liabilities | 16M |
| Shareholder Equity | 400M |
| Total Debt | 0 |
| Net Debt | -736K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
633K
Capital Expenditures
4
Free Cash Flow
633K
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.